Patient selection biomarker strategies for PARP inhibitor therapy
- PMID: 33011228
- DOI: 10.1016/j.annonc.2020.09.017
Patient selection biomarker strategies for PARP inhibitor therapy
Conflict of interest statement
Disclosure TAY has received research support (to institution) from Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals; reports consulting for Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian, and Zai Labs Patrick. AG reports consulting/honoraria (to department or self) for/from Astra Zeneca, Clovis, GSK, Merck, Pfizer, Roche. PGP has declared no conflicts of interest.
Comment on
-
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28. Ann Oncol. 2020. PMID: 33004253
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
